A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma. A next-generation "armored" CAR T cell therapy ...
A pioneering preclinical study has shown that CAR T cell therapy-a personalized form of immunotherapy used in cancer treatment-could be a highly effective tool against atherosclerosis, the condition ...
Parkinson's disease (PD) is an age-related, progressive, neurodegenerative condition, caused by loss of dopamine-producing neurons. To overcome the shortcomings of conventional levodopa-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results